. Erratum: Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD J Clin Oncol 2023 Jun 26:JCO2301239. doi: 10.1200/JCO.23.01239.
PMID: 37364222